Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 8Stomach Neoplasms 6Uterine Cervical Neoplasms 2Non-Muscle Invasive Bladder Neoplasms 2Carcinoma, Transitional Cell 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Solid Tumor 1Prostatic Neoplasms 1Ovarian Neoplasms 1Ovarian Cancer Recurrent 1Metastatic HER2 Positive Gastroesophageal Junction Cancer 1Lung Neoplasms 1High-risk Non-muscle Invasive Bladder Cancer 1HER2-positive Metastatic Breast Cancer 1HER2-low Breast Cancer 1Castration-resistant Prostate Cancer 1Advanced Breast Cancer 1

Interventions

Fulvestrant 4trastuzumab deruxtecan 2elacestrant 2Vinorelbine 2AZD9833 2toripalimab 1talazoparib 1ribociclib 1pyrotinib 1palbociclib 1olaparib 1exemestane 1eribulin 1disitamab vedotin 1dalpiciclib 1apatinib 1abemaciclib 1Selective Estrogen Receptor Modulators 1Radiotherapy 1RAD1901 1Letrozole 1Injections 1Gonadotropin-Releasing Hormone 1Everolimus 1Capecitabine 1Aromatase Inhibitors 1Anastrozole 1AZD5305 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Advanced Breast Cancer × disitamab vedotin × Clear all
NCT05831878 2026-05-13

RC48-ADC in HER2-low Advanced Breast Cancer

RenJi Hospital

Phase NA Recruiting
36 enrolled
Breast

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡